{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T13:08:24Z","timestamp":1706015304886},"reference-count":38,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Case 1: A 23-year-old female third-year medical student who has no medical history seeks treatment for abdominal distention. She takes an estrogen-containing birth control pill and does not smoke or consume alcohol. Family history is unremarkable. Physical examination is significant for abdominal distention, and an abdominal fluid wave is detected. Complete blood count is normal. Imaging confirms occlusive thrombosis of the main portal vein. On endoscopy, grade 1 to 2 esophageal varices are noted and banded. Unfractionated heparin is begun. Subsequent workup reveals a homozygous factor V Leiden mutation. Long-term anticoagulation is planned, and she asks if warfarin can be avoided given her hectic ward rotations, erratic diet, and need for monitoring. Case 2: A 35-year-old woman who has no medical history seeks treatment for progressively worsening posterior headaches for 1 week. Magnetic resonance imaging of the brain shows dural sinus thrombosis with associated small areas of petechial cerebral hemorrhage. She is started on a continuous unfractionated heparin infusion and admitted to the hospital for further observation. Her grandmother is on warfarin for atrial fibrillation, and the patient would prefer to avoid warfarin because she does not think she can comply with the frequent monitoring that will be required. She inquires about other oral anticoagulant options for her condition.<\/jats:p>","DOI":"10.1182\/hematology.2021000319","type":"journal-article","created":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T12:06:42Z","timestamp":1639138002000},"page":"100-105","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Evidence-Based Minireview: Should warfarin or a direct oral anticoagulant be used in patients presenting with thrombosis in the splanchnic or cerebral veins?"],"prefix":"10.1182","volume":"2021","author":[{"given":"Carol","family":"Mathew","sequence":"first","affiliation":[{"name":"University of Florida, Internal Medicine, Division of Hematology\/Oncology, Gainesville, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Zumberg","sequence":"additional","affiliation":[{"name":"University of Florida, Internal Medicine, Division of Hematology\/Oncology, Gainesville, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2021,12,10]]},"reference":[{"issue":"7","key":"2021121012063504100_hem2021000319C1","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1111\/jth.14836","article-title":"Anticoagulant therapy for splanchnic vein thrombosis: ISTH SSC subcommittee control of anticoagulation","volume":"18","author":"Di Nisio","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2021121012063504100_hem2021000319C2","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jhep.2015.07.040","article-title":"EASL clinical practice guidelines: vascular diseases of the liver","volume":"64","author":"European Association for the Study of the Liver","year":"2016","journal-title":"J Hepatol"},{"issue":"2, suppl","key":"2021121012063504100_hem2021000319C3","doi-asserted-by":"crossref","first-page":"e419S","DOI":"10.1378\/chest.11-2301","article-title":"Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Kearon","year":"2012","journal-title":"Chest"},{"issue":"9","key":"2021121012063504100_hem2021000319C4","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1182\/blood.2020006827","article-title":"Anticoagulant therapy for splanchnic vein thrombosis: a systematic review and meta-analysis","volume":"137","author":"Valeriani","year":"2021","journal-title":"Blood"},{"issue":"7","key":"2021121012063504100_hem2021000319C5","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1055\/s-0040-1722192","article-title":"Anticoagulant treatment for splanchnic vein thrombosis in liver cirrhosis: a systematic review and meta-analysis","volume":"121","author":"Valeriani","year":"2021","journal-title":"Thromb Haemost"},{"issue":"1","key":"2021121012063504100_hem2021000319C6","first-page":"104","article-title":"Efficacy and safety of anticoagulation in non-malignant portal vein thrombosis in patients with liver cirrhosis: a systematic review and meta-analysis","volume":"34","author":"Ghazaleh","year":"2021","journal-title":"Ann Gastroenterol"},{"issue":"3","key":"2021121012063504100_hem2021000319C7","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1161\/01.STR.30.3.484","article-title":"Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis","volume":"30","author":"de Bruijn","year":"1999","journal-title":"Stroke"},{"issue":"3","key":"2021121012063504100_hem2021000319C8","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1161\/01.STR.0000117571.76197.26","article-title":"Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT)","volume":"35","author":"Ferro","year":"2004","journal-title":"Stroke"},{"issue":"2","key":"2021121012063504100_hem2021000319C9","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/rth2.12480","article-title":"Direct oral anticoagulants for unusual-site venous thromboembolism","volume":"5","author":"Riva","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"2","key":"2021121012063504100_hem2021000319C10","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"issue":"19","key":"2021121012063504100_hem2021000319C11","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv"},{"key":"2021121012063504100_hem2021000319C12","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.vph.2018.05.002","article-title":"Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis","volume":"113","author":"Hanafy","year":"2019","journal-title":"Vascul Pharmacol"},{"issue":"1","key":"2021121012063504100_hem2021000319C13","doi-asserted-by":"crossref","first-page":"e13356","DOI":"10.1111\/eci.13356","article-title":"Outcomes of long-term anticoagulant treatment for the secondary prophylaxis of splanchnic venous thrombosis","volume":"51","author":"Serrao","year":"2021","journal-title":"Eur J Clin Invest"},{"issue":"4","key":"2021121012063504100_hem2021000319C14","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1182\/bloodadvances.2019001310","article-title":"The efficacy and safety of direct oral anticoagulants in noncirrhotic portal vein thrombosis","volume":"4","author":"Naymagon","year":"2020","journal-title":"Blood Adv"},{"key":"2021121012063504100_hem2021000319C15","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.thromres.2021.03.018","article-title":"Splanchnic vein thrombosis: clinical manifestations, risk factors, management, and outcomes","volume":"202","author":"Kawata","year":"2021","journal-title":"Thromb Res"},{"issue":"4","key":"2021121012063504100_hem2021000319C16","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/jgh.14843","article-title":"Dabigatran as an oral anticoagulant in patients with Budd-Chiari syndrome post-percutaneous endovascular intervention","volume":"35","author":"Sharma","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"2021121012063504100_hem2021000319C17","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/0268355518779517","article-title":"Evaluation of direct oral anticoagulants and vitamin K antagonists in mesenteric venous thrombosis","volume":"34","author":"Salim","year":"2019","journal-title":"Phlebology"},{"issue":"2","key":"2021121012063504100_hem2021000319C18","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial","volume":"18","author":"McBan","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"7","key":"2021121012063504100_hem2021000319C19","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"issue":"20","key":"2021121012063504100_hem2021000319C20","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"issue":"17","key":"2021121012063504100_hem2021000319C21","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"2021121012063504100_hem2021000319C22","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1001\/jamaneurol.2019.2764","article-title":"Safety and efficacy of dabigatran etexilate vs dose-adjusted warfarin in patients with cerebral venous thrombosis: a randomized clinical trial","volume":"76","author":"Ferro","year":"2019","journal-title":"JAMA Neurol"},{"issue":"4","key":"2021121012063504100_hem2021000319C23","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2021121012063504100_hem2021000319C24","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1007\/s11239-020-02106-7","article-title":"Comparing the efficacy and safety of direct oral anticoagulants with vitamin K antagonist in cerebral venous thrombosis","volume":"50","author":"Lee","year":"2020","journal-title":"J Thromb Thrombolysis"},{"issue":"2","key":"2021121012063504100_hem2021000319C25","doi-asserted-by":"crossref","first-page":"e040212","DOI":"10.1136\/bmjopen-2020-040212","article-title":"Direct oral anticoagulants in treatment of cerebral venous thrombosis: a systematic review","volume":"11","author":"Bose","year":"2021","journal-title":"BMJ Open"},{"issue":"2","key":"2021121012063504100_hem2021000319C26","doi-asserted-by":"crossref","first-page":"220","DOI":"10.5853\/jos.2019.00150","article-title":"New oral anticoagulants versus warfarin for cerebral venous thrombosis: a multi-center, observational study","volume":"21","author":"Wasay","year":"2019","journal-title":"J Stroke"},{"issue":"5","key":"2021121012063504100_hem2021000319C27","first-page":"384","article-title":"Direct oral anticoagulants in the treatment of cerebral venous sinus thrombosis: a single institution's experience","volume":"53","author":"Rusin","year":"2019","journal-title":"Neurol Neurochir Pol"},{"key":"2021121012063504100_hem2021000319C28","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.clineuro.2018.10.015","article-title":"Is it safe to treat cerebral venous thrombosis with oral rivaroxaban without heparin? A preliminary study from 20 patients","volume":"175","author":"Shankar Iyer","year":"2018","journal-title":"Clin Neurol Neurosurg"},{"issue":"8","key":"2021121012063504100_hem2021000319C29","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1161\/STROKEAHA.114.006167","article-title":"Novel factor Xa inhibitor for the treatment of cerebral venous and sinus thrombosis: first experience in 7 patients","volume":"45","author":"Geisb\u00fcsch","year":"2014","journal-title":"Stroke"},{"issue":"7","key":"2021121012063504100_hem2021000319C30","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/ijs.12462","article-title":"Oral direct thrombin inhibitor as an alternative in the management of cerebral venous thrombosis: a series of 15 patients","volume":"10","author":"Mendon\u00e7a","year":"2015","journal-title":"Int J Stroke"},{"issue":"3","key":"2021121012063504100_hem2021000319C31","first-page":"3","article-title":"Treatment of cerebral venous thrombosis with rivaroxaban","volume":"5","author":"Anticoli","year":"2016","journal-title":"J Biomed Sci"},{"issue":"4","key":"2021121012063504100_hem2021000319C32","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/ene.12901","article-title":"Frequency and temporal profile of recanalization after cerebral vein and sinus thrombosis","volume":"23","author":"Herweh","year":"2016","journal-title":"Eur J Neurol"},{"key":"2021121012063504100_hem2021000319C33","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.thromres.2018.11.018","article-title":"Apixaban and rivaroxaban in patients with cerebral venous thrombosis","volume":"173","author":"Covut","year":"2019","journal-title":"Thromb Res"},{"issue":"1","key":"2021121012063504100_hem2021000319C34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12959-021-00300-y","article-title":"Thrombosis and bleeding outcomes in the treatment of cerebral venous thrombosis in cancer","volume":"19","author":"Abelhad","year":"2021","journal-title":"Thromb J"},{"issue":"7","key":"2021121012063504100_hem2021000319C35","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/rth2.12424","article-title":"Anticoagulation in splanchnic and cerebral vein thrombosis: an international vignette-based survey","volume":"4","author":"Riva","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"3","key":"2021121012063504100_hem2021000319C36","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3390\/jcm9030743","article-title":"Cerebral and splanchnic vein thrombosis: advances, challenges, and unanswered questions","volume":"9","author":"Riva","year":"2020","journal-title":"J Clin Med"},{"issue":"4","key":"2021121012063504100_hem2021000319C37","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.ejvs.2017.01.010","article-title":"Editor's choice\u2014management of the diseases of mesenteric arteries and veins: clinical Practice Guidelines of the European Society of Vascular Surgery (ESVS)","volume":"53","author":"Bj\u00f6rck","year":"2017","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"10","key":"2021121012063504100_hem2021000319C38","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/ene.13381","article-title":"European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis\u2014endorsed by the European Academy of Neurology","volume":"24","author":"Ferro","year":"2017","journal-title":"Eur J Neurol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2021\/1\/100\/1851729\/100mathew.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2021\/1\/100\/1851729\/100mathew.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T12:07:11Z","timestamp":1639138031000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2021\/1\/100\/482943\/Evidence-Based-Minireview-Should-warfarin-or-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,10]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12,10]]},"published-print":{"date-parts":[[2021,12,10]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2021000319","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,10]]},"published":{"date-parts":[[2021,12,10]]}}}